Hutchin Hill Capital’s Supernus Pharmaceuticals SUPN Stock Holding History

Hutchin Hill Capital’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-34,204	Closed	-$1.37M	–	672
2017 Q3	$1.37M	Buy	+34,204	New	+$1.48M	0.05%	281
2017 Q2	–	Sell	-29,400	Closed	-$920K	–	1031
2017 Q1	$920K	Buy	+29,400	New	+$788K	0.03%	496
2016 Q4	–	Sell	-12,500	Closed	-$309K	–	834
2016 Q3	$309K	Buy	+12,500	New	+$283K	0.01%	515
2015 Q4	–	Sell	-74,005	Closed	-$1.04M	–	750
2015 Q3	$1.04M	Sell	74,005 -54,295	-42%	-$1.01M	0.04%	409
2015 Q2	$2.18M	Buy	128,300 +48,300	+60%	+$687K	0.06%	309
2015 Q1	$967K	Buy	80,000 +17,600	+28%	+$166K	0.03%	446
2014 Q4	$518K	Buy	+62,400	New	+$524K	0.02%	444

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

RCAMU

Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return

Hutchin Hill Capital's SUPN Position: Q4 2017 in Review

Hutchin Hill Capital sold out of Supernus Pharmaceuticals (SUPN) in Q4 2017, closing a stake of 34,204 shares — an estimated $1.37M sold.

Hutchin Hill Capital first reported a position in SUPN in Q4 2014 and held it in 7 quarters. The position peaked at $2.18M in Q2 2015. 297 funds tracked by Wall St. Rank hold SUPN as of Q4 2017.

Hutchin Hill Capital reported no remaining Supernus Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
Hutchin Hill Capital sold 34,204 Supernus Pharmaceuticals shares in Q4 2017, an estimated $1.37M.
Hutchin Hill Capital first reported a position in Supernus Pharmaceuticals in Q4 2014 and held it in 7 quarters.
Hutchin Hill Capital's Supernus Pharmaceuticals position peaked at $2.18M in Q2 2015.
297 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2017.

Based on Hutchin Hill Capital's 13F filing for Q4 2017, filed 12 Feb 2018.